SGMO News and Press, Sangamo Therapeutics Inc. From 07/29/21

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its second quarter 2021 financial results after the market closes on Thursday, August 5, 2021. The press release will be followed by a conference call at ...

Brian Ach/Getty Images Entertainment Intellia Therapeutics ([[NTLA]] +7.7%) has gained more than 80.0% since the company joined Gilead Sciences ([[GILD]] +1.2%) over the weekend to unveil the first first-ever clinical data to support the safety and efficacy of in-vivo CRISPR genome editi...

PhonlamaiPhoto/iStock via Getty Images Biotech companies that are focused on the gene editing space for treatments are continuing higher for the third straight day. Beam Therapeutics ([[BEAM]] +15.7%) and Editas Medicine ([[EDIT]] +16.6%) are up double-digit percentages. CRISPR Therapeutics (...

CRISPR can be utilized ubiquitously as a search and replace tool allowing scientists to identify DNA sequences. The potential uses of CRISPR are numerous across a large variety of fields including agriculture, chemical, pharmaceutical, and livestock industries. Emerging biotech co...

Intellia Therapeutics (NTLA) +58%. after releasing interim data from a phase 1 trial of a CRISPR candidate.Marin Software Incorporated (MRIN) +38%.ReShape Lifesciences (RSLS) +34%.Anavex Life Sciences (AVXL) +24% after after ANAVEX2-73 improved endpoints in Phase 2 Parkinson’s dis...

BioMarin product revenue has begun to decline. The outlook and guidance for 2021 is consistent with the modest decline reported in the first quarter. The next catalyst is likely November 2021 which is the scheduled PDUFA date for Vosoritide. Roctavian remains the most signifi...

BioMarin stock remains depressed since the August CRL. There are major catalysts ahead. BMRN has a solid cash balance and revenue stream. For further details see: BioMarin: Depressed Price Due To CRL, Major Catalysts Ahead

Sangamo and licensee Pfizer's SB-525 is competing with BioMarin's ValRox in hemophilia A. There are durability questions surrounding both drugs. However, they will have a positive role to play in this indication. For further details see: Sangamo's Hemophilia A Treatment:...

Sangamo Therapeutics (SGMO) announces the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021.Ms. Duraibabu joined Sangamo in March 2019 and has served as Principal Accounting Officer for nearly two years. She has over 20 ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4 th at 11am Eastern Time. The virtual session will be webcast live and may be access...